Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JSI-1187 Monotherapy and Combo with Dabrafenib in MAPK-Mutated Solid Tumors
NCT04418167Phase 1Suspended
- Sponsor
- JS InnoPharm
- Start
- Jun 2020
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of JSI-1187 in solid tumor (advanced stage), melanoma, non-small cell lung cancer (NSCLC) and 1 more (3 arms), sponsored by JS InnoPharm. Primary endpoint: Incidence of treatment emergent adverse events at 35 months. Started Jun 2020; status: suspended.
02
Drugs
JSI-1187
03
Conditions
solid tumor (advanced stage)melanomanon-small cell lung cancer (NSCLC)anaplastic thyroid cancer (ATC)
Beyond the preview
Go deeper on NCT04418167.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04418167.